• Biogen plans to advance investigational tau-targeting ASO diranersen into confirmatory Phase 3 trials in early Alzheimer’s disease.
• Phase 2 CELIA missed its primary endpoint on dose response in CDR-SB at 18 months, with no added benefit at higher doses.
• 60 mg every six months showed the strongest signal vs placebo: 26% less decline on CDR-SB, 42% on ADAS-Cog13, 50% on MMSE.
• Biomarkers showed mean CSF total tau reductions of 50%-65%; tau PET also declined across evaluated brain regions.
• Safety profile was generally tolerable; most common events were procedural pain, post-lumbar puncture syndrome, confusional state.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607140915PRIMZONEFULLFEED9761736) on July 14, 2026, and is solely responsible for the information contained therein.